Intuitive Surgical stock steadies ahead of Q2 2026 earnings report

Published on 09/04/2026 at 06:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock is trading firmly ahead of its Q2 2026 earnings release, with investors watching the robotic surgery leader’s growth metrics and margins alongside its large market capitalization.

Aquarellillustration eines modernen Technologiecampus mit Palmen und Glasgebäuden in Sunnyvale — Aquarellmalerei des Firmensitzes in Sunnyvale zeigt Intuitive Surgical Inc. (US46120E6023) mit modernem Campus und Palmen, Illustration mit AI erstellt.

Intuitive Surgical stock (ISIN US46120E6023) is drawing investor attention ahead of the company’s Q2 2026 earnings release, with market data on September 3, 2026 pointing to a market capitalization of about USD 142.05 billion according to a coverage overview by 247wallst.

Robotic surgery leader heads into Q2 2026 report

According to an earnings preview published by 247wallst on September 3, 2026, Intuitive Surgical is scheduled to report its Q2 2026 results after the US market close at 4:40 PM ET, underscoring the near term catalyst for the stock.

The same overview cites the company as a robotic surgery leader entering this earnings event with a market capitalization of roughly USD 142.05 billion as of early September 2026, a figure that helps frame the valuation investors are weighing against growth and margin trends.

Market data and valuation context

While detailed intraday price data for Intuitive Surgical stock on September 4, 2026 was not highlighted in the available sources, the earnings preview context with a USD 142.05 billion market capitalization as of September 3, 2026 provides a clear yardstick for how much value the market currently assigns to the company’s installed base and recurring procedure revenue.

For investors, this large capitalization means that any surprise in Q2 2026 figures, whether on procedure growth or margins, can translate into significant absolute market value changes even when percentage moves in the share price remain moderate.

Go deeper

More on Intuitive Surgical stock and filings

Further details on Intuitive Surgical stock, including historical filings and additional news, can be found via the company overview and topic pages.

All news and filings on this ISIN Investor Relations

da Vinci system as a core product

Intuitive Surgical’s flagship product is the da Vinci robotic surgery system, which is widely used in minimally invasive procedures across urology, gynecology and general surgery worldwide and forms the backbone of the company’s recurring revenue model.

Stock perspective around the Q2 2026 release

With Intuitive Surgical stock backed by a market capitalization of about USD 142.05 billion as of September 3, 2026, the upcoming Q2 2026 earnings release is set to update investors on how procedure volumes and system placements are supporting that valuation in the medium term.